



QUARTERLY COMPLIANCE REPORT ON CORPORATE GOVERNANCE

Name of the Listed Entity : ASTRAZENECA PHARMA INDIA LIMITED  
 Quarter ending : December 31, 2018

**ANNEXURE 1**

I. Composition of Board Directors									
Title (Mr./Ms.)	Name of the Director	PAN	DIN	Category (Chairperson/Executive/Non- Executive/ Independent/Nominee)	Date of Appointment in the current term/cessation	Tenure*	No. of Directorship in listed entity (Refer Regulation 25(1) of Listing Regulations)	No. of Memberships in Audit/Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No. of Post of Chairperson in Audit/Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
Mr.	NARAYAN KEELVEEDHI SESHADRI	AAVPS2486D	00053563	Non-Executive/Independent	30/09/2014	5 years	6	6	3
Ms.	REVATHY ASHOK KIMSUKA	ACLPR3951Q	00057539	Non-Executive/Independent	02/12/2016	5 years	4	6	3
Ms.	NARASIMHAN GAGANDEEP SINGH BEDI	AAKPK7372B	02102783	Non-Executive/Independent	02/02/2017	5 years	2	1	0
Mr.	GREGORY DAVID EMIL MUELLER	PAN not available	07844333	Executive	01/07/2017		1	1	0
Mr.	IAN JOHN PARISH	PAN not available	07667074	Non-Executive	02/12/2016		1	1	0
Mr.	RAJESH MARWAHA	AAAAPM1413D	00391534	Non-Executive	08/08/2017		1	0	0
			01458768	Executive	02/12/2016		1	1	0



II. Composition of Committees		
Name of Committee	Name of Committee members	Category(Chairperson/Executive/Non-Executive/Independent/Nominee)
Audit Committee	1. Ms. REVATHY ASHOK	Chairperson/Non-Executive/Independent
	2. Mr. NARAYAN K SESHADRI	Non-Executive/Independent
	3. Mr. GREGORY DAVID EMIL MUELLER	Non-Executive
Nomination and Remuneration Committee	1. Ms. KIMSUKA NARASIMHAN	Chairperson/Non-Executive/Independent
	2. Mr. NARAYAN K SESHADRI	Non-Executive/Independent
	3. Mr. GREGORY DAVID EMIL MUELLER	Non-Executive
	4. Mr. IAN JOHN PARISH	Non-Executive
Stakeholders' Relationship Committee	1. Ms. REVATHY ASHOK	Chairperson/Non-Executive/Independent
	2. Mr. GAGANDEEP SINGH BEDI	Executive
	3. Mr. RAJESH MARWAHA	Executive

III. Meeting of Board of Directors		
Date(s) of Meeting (If any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive meetings (in number of days)
13 August 2018	13 November 2018	91

IV. Meeting of Committees			
Date(s) of meeting of the Committee in the relevant quarter	Whether requirement of Quorum met (details)	Date (s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days*
<b>Audit Committee</b>			
13 November 2018	Yes	13 August 2018	91
<b>Stakeholders' Relationship Committee</b>			
13 November 2018	Yes	-	-

V. Related Party Transactions	
Subject	Compliance status (Yes / No / NA) refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit committee	Yes

Details of material transactions with Related Party for the quarter ended December 31, 2018

Name of the Related Party: **AstraZeneca UK Limited**

Type of Transaction	Amount (INR)
Imports	608,927,290
Payable of Expenses	17,234,201
Reimbursement of Expenses	911,359
<b>Total</b>	<b>627,072,850</b>



1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
2. The Composition of the following committees is in terms of SEBI (listing Obligations and Disclosure requirements) Regulations, 2015
  - a) Audit Committee
  - b) Nomination & Remuneration Committee
  - c) Stakeholders Relationship Committee
3. The Committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements Regulations, 2015
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
5. This report and /or the report submitted in the previous quarter has been placed before Board of Directors.

Any comments/observations/advice of Board of Directors may be mentioned here:  
NIL

For AstraZeneca Pharma India Limited



Pratap Rudra  
Company Secretary & Legal Counsel

